ikenaoncology.com (IMA) - Company Total Revenue
A stable patent moat in the field of targeted immuno-oncology ensures the resilience of ImageneBio Inc. The operating model relies on outsourcing clinical trials to optimize R&D costs. The company's sales revenue on the chart confirms demand dynamics, where the indicator value reaches 0.00. Growth potential is driven by successes in precision cancer therapy and new partnerships.
Comprehensive metric breakdowns and analytics for ImageneBio (IMA)
- current price and projected stock value:
- market capitalization indicators:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital ImageneBio Inc|IMA - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Ikena Oncology, Inc.|IMA - Company Aggregate Debts|Debts to Book Value ImageneBio Inc|IMA - Company Long-Term Debt|Company Short-Term Indebtedness Ikena Oncology|Immediate Liquidity ikenaoncology.com
- earnings and market multiples details:
IMA - Net Profit|Expected Profit ImageneBio Inc|IMA - P/E Multiple|Market Cap to Projected Earnings Ikena Oncology, Inc.|IMA - Price/Earnings to Growth Ratio|Company Value to EBITDA ImageneBio Inc|IMA - Operating profit before deduction of amortization|Earnings per share for the trailing year Ikena Oncology|IMA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months ikenaoncology.com|IMA - Earnings per share growth in current year|Projected earnings per share growth rate for next year ImageneBio Inc
- sales volume and revenue indicators:
Summary company analysis:IMA (ikenaoncology.com)
Investors are assessing the potential of ImageneBio Inc (IMA) through the company's ability to monetize its scientific developments. This metric represents the aggregate of all daily commercial inflows, reflecting the actual cash flow from product sales. Analyzing the company's operational sales allows for the timely detection of liquidity declines during price stagnation. Stable revenue growth confirms the effectiveness of investments in elite biologists and costly targeted therapy programs.
Analysis of competing companies
Company Sales Volume ARGX (argenx BVBA)|Revenue and Sales Volume BNTX|ABVX - Company Total Revenue|Revenue and Sales Volume ADMA (ADMA Biologics, Inc.)|Company Gross Revenue Protagonist Therapeutics, Inc. (PTGX)|IMVT - Company Revenue|Kiniksa Corp (KNSA) - Company Sales|GRFS: Revenue and Sales Volume|adaptivebiotech.com (ADPT) - Revenue and Sales Volume|CLDX (Celldex Therapeutics, Inc.) - Revenue and Sales Volume|AUPH - Company Total Sales Volume|Revenue and Sales Volume BCRX|VERA - Company Total Revenue|Company Revenue Dianthus Therapeutics DNTH|PHVS: Company Sales Volume|AbCellera - Revenue and Sales Volume|Company Total Revenue Tourmaline Bio Inc|PGEN: Revenue and Sales Volume|PHAR (Pharming Corp) - Company Revenue|NKTR (Nektar Therapeutics) - Revenue and Sales Volume|upstreambio.com (UPB) - Company Gross Revenue|Company Revenue Zenas Biopharma (ZBIO)|IMNM - Company Total Revenue|Gossamer Corp - Company Sales|Company Sales Revenue KALV|Septerna Inc - Revenue and Sales Volume|Company Gross Revenue pieris.com PVLA|Savara (SVRA) - Company Revenue|Company Sales Volume RIGL|ANAB (AnaptysBio Corp) - Revenue and Sales Volume|Company Sales Astria Corp (ATXS)|Revenue and Sales Volume ENGN|Company Gross Revenue rapt.com|Company Revenue Aerovate Therapeutics JBIO|ACRS - Company Sales|Kyverna - Revenue and Sales Volume|TLSA - Revenue and Sales Volume|Cabaletta Bio, Inc. (CABA) - Company Revenue|Company Annual Revenue VTYX (ventyxbio.com)|THTX (Theratechnologies) - Revenue and Sales Volume|AVTX: Company Sales Revenue|Revenue and Sales Volume ELDN|Revenue and Sales Volume Agenus, Inc (AGEN)|Company Revenue Climb Bio Inc CLYM|Company Sales Revenue ZURA|ATYR - Company Revenue|Adagene (ADAG) - Company Sales|STTK: Revenue and Sales Volume|Equillium (EQ) - Revenue and Sales Volume|Company Sales CNTB|IMUX: Company Sales Revenue|Revenue and Sales Volume ATRA|Company Gross Revenue inflarx.de|Company Revenue X4 Pharma XFOR|ACET - Company Sales|CELU - Company Revenue|inmunebio.com (INMB) - Company Sales|BRNS (Barinthus Biotherapeutics plc) - Company Sales|Kezar Life Sciences Inc. (KZR) - Revenue and Sales Volume|Company Revenue SAB Biotherapeutics, Inc|Company Sales Volume AKTX (Akari Therapeutics, Plc)|Revenue and Sales Volume ENLV|QTTB - Company Total Revenue|Revenue and Sales Volume GOVX (GeoVax)|Company Gross Revenue Edesa Biotech Inc (EDSA)|IBIO - Company Revenue|Carisma Therapeutics (CARM) - Company Sales|XTLB: Revenue and Sales Volume|Bolt Biotherapeutics, Inc. (BOLT) - Revenue and Sales Volume|HCWB (HCW Biologics, Inc.) - Revenue and Sales Volume|APVO - Company Total Sales Volume|Revenue and Sales Volume AIM|ADTX - Company Total Revenue|Company Revenue GRI Bio, Inc. GRI|XRTX: Company Sales Volume|Vyome Holdings - Revenue and Sales Volume|Company Total Revenue Revelation Biosciences Inc|INDP: Revenue and Sales Volume|SCNI (BiondVax Pharmaceuticals) - Company Revenue|CALI (CalciMedica Inc) - Revenue and Sales Volume|Affimed Therapeutics (AFMD) - Company Gross Revenue|Company Revenue Allakos Inc. (ALLK)|HOOK - Company Total Revenue|IGM Biosciences - Company Sales|Company Sales Revenue ITOS|Ocean Biomedical, Inc. - Revenue and Sales Volume|Company Gross Revenue tcbiopharm.com TCBP|Third Harmonic Bio, Inc. (THRD) - Company Revenue
